GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Total Liabilities

Paion Ag (Paion Ag) Total Liabilities : $38.25 Mil (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Total Liabilities?

Paion Ag's Total Liabilities for the quarter that ended in Jun. 2023 was $38.25 Mil.

Paion Ag's quarterly Total Liabilities increased from Jun. 2022 ($30.36 Mil) to Dec. 2022 ($33.43 Mil) and increased from Dec. 2022 ($33.43 Mil) to Jun. 2023 ($38.25 Mil).

Paion Ag's annual Total Liabilities increased from Dec. 2020 ($8.35 Mil) to Dec. 2021 ($33.66 Mil) but then declined from Dec. 2021 ($33.66 Mil) to Dec. 2022 ($33.43 Mil).


Paion Ag Total Liabilities Historical Data

The historical data trend for Paion Ag's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Total Liabilities Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.98 11.31 8.35 33.66 33.43

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.62 33.66 30.36 33.43 38.25

Paion Ag Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Paion Ag's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.364+(20.042+0.027999999999995
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=33.43

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=40.442-7.007
=33.44

Paion Ag's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=18.205+(20.018+0.024999999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=38.25

Total Liabilities=Total Assets (Q: Jun. 2023 )-Total Equity (Q: Jun. 2023 )
=34.926--3.322
=38.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paion Ag Total Liabilities Related Terms

Thank you for viewing the detailed overview of Paion Ag's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Paion Ag (Paion Ag) Business Description

Traded in Other Exchanges
Address
Heussstrasse 25, Aachen, DEU, 52078
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.